Our ENZAMET trial was a large, international randomised trial to determine if treatment with the hormone therapy enzalutamide could improve survival and quality of life in men starting hormone treatment for newly diagnosed metastatic prostate cancer. The trial was led by ANZUP involving 1,125 men from Australia, New Zealand, Canada, USA, United Kingdom, and Ireland.
Study Co-Chair and Board Chair of ANZUP, Professor Ian Davis, said, “ENZAMET is a unique collaboration of clinicians and scientists from Australia, New Zealand, Ireland, UK, Canada, and the USA, all coming together to work with the community to find better ways of treating prostate cancer. ENZAMET won the 2020 Trial of the Year Award, as well as awards for community involvement, and for high quality statistical conduct. Now we have very mature results confirming that the benefit of enzalutamide treatment persists even after much longer follow-up, and we continue to see other informative results emerging from this very important trial.”ANZUP's TheraP trial was the first randomised trial comparing 177Lu-PSMA-617 (Lu-PSMA), a novel radioactive treatment, to the current standard-of-care chemotherapy called cabazitaxel for people with metastatic castration-resistant prostate cancer. These people had disease that had already progressed after standard chemotherapy.
Study Chair Prof. Michael Hofman, of the Peter MacCallum Cancer Centre, said “Three year follow-up of the TheraP study provides compelling evidence that 177Lu-PSMA-617 is a new treatment option for people with prostate cancer, providing an alternative to cabazitaxel chemotherapy with better patient reported outcomes and lower side effects.”
Source: "News – ANZUP". 2022. ANZUP. https://anzup.org.au/news/.
ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)